Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Supplemental Cash Flow Information

9 Months Ended

Sep. 30, 2018

13.

SUPPLEMENTAL CASH FLOW INFORMATION

The following table presents cash flows used in the Company’s discontinued operations for the nine months ended September 30, 2018 and 2017:

	Nine Months Ended
	September 30,
	2018			2017
	(unaudited)
Net cash used in operating activities of discontinued operations	$	(376	)	$	(2,259	)

Supplemental Cash Flow Information

(in thousands)

	Nine Months Ended
	September 30,
	2018		2017
	(unaudited)
Operating
Adoption of ASC 606	$	2,500	$	-
Prepaid stock grants issued to vendors	$	257	$	-

Investing
Acquisition of property and equipment in other accrued expenses	$	12	$	-
Tenant incentives recorded as part of deferred rent	$	-	$	84

Financing
Settlement of the RedPath Note	$	-	$	(8,098	)
Issuance of the Exchange Notes	$	-	$	11,375
Common shares issued in debt exchange	$	-	$	8,869

*See Note 14, Equity